^
Association details:
| Biomarker: | TSC2 deletion |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | everolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus
Excerpt:
TSC2 loss in hepatocellular carcinoma cell lines confers everolimus sensitivity…Everolimus was significantly more potent and tended to be more efficacious in TSC2-null cell lines (red color) than in TSC2 wild-type cell lines…these results strongly suggest that TSC2 loss is a highly penetrant predictive biomarker for everolimus sensitivity in HCC cell lines.
DOI:
10.1158/1535-7163.MCT-14-0768
